Stanford Journal of Law Science & Policy, Vol. 3, p. 17, 2010
20 Pages Posted: 28 Dec 2010
Date Written: December 1, 2009
Beginning in 2006, induced pluripotent stem cells have raised the tantalizing possibility that stem cell research could move forward without the significant moral and ethical dilemmas that have paralyzed the field. These cells, known as iPS cells, originate from adult somatic cells, but function in a manner that is almost equivalent to embryonic stem cells. If iPS cell research lives up to its promise, stem cell research, diagnostics, and treatment could be accomplished without destroying or in any way interfering with human embryos or their development.
While we may be entering a historic moment in stem cell research, we are also facing a historic period in American patent law. Of the five key principles of patentability, three are currently in flux, creating challenges for those who would navigate the system. In the brief space allotted here, we will survey the shifting landscape in American patent law, as it may affect the rights available to iPS cell inventors. This brief overview may serve not only as an alert for scientists in the field, but also as a reminder to those of us in the patent world that our failure to resolve doctrinal uncertainties can have a tangible effect on scientific research.
Keywords: patent, stem cells, iPS cells, biotechnology, life science, life sciences, law and science, law & science
Suggested Citation: Suggested Citation
Feldman, Robin and Furth, Deborah, The Intellectual Property Landscape for IPS Cells (December 1, 2009). Stanford Journal of Law Science & Policy, Vol. 3, p. 17, 2010. Available at SSRN: https://ssrn.com/abstract=1731652